

10/526025
BT01 Rec'd PCT/PT 28 FEB 2005

AMENDMENTS TO THE CLAIMS

1 (Currently amended). A method of treatment of a patient in need of modulation of body mass or modulation of increase in body mass, and/or in need of modulation of plasma insulin, plasma glucose, plasma triglycerides and/or plasma cholesterol, comprising administering to the patient an effective amount of a compound comprising perfluorooctanoic acid or a salt (~~preferably other than ammonium salt, preferably other than 75% straight chain ammonium salt~~) or an ester thereof[;], perfluorosuberic acid, perfluoroheptanoic acid, perfluorohexanoic acid, perfluoropentanoic acid, perfluorobutanoic acid or perfluoropropionic acid or a salt or an ester any thereof[;], or perfluorooctane.

2 (Currently amended). A The method of claim 1 of treatment of a wherein the patient is in need of an antitumour agent or an antiinflammatory agent, or in need of modulation in lipid or eicosanoid status; ~~comprising administering to the patient an effective amount of a compound as defined in claim 1.~~

3 (Currently amended). A The method of claim 1 of treatment of a wherein the patient who is overweight or obese and/or has diabetes, hyperlipidaemia, atherosclerosis, coronary heart disease, stroke, obstructive sleep apnoea, arthritis and/or reduced fertility, or is at risk of developing such a condition; ~~comprising administering to the patient an effective amount of a compound as defined in claim 1.~~

4 (Currently amended). A The method of claim 1 of treatment of a wherein the patient is in need of modulation of PPAR (~~for example PPAR α~~) activity; ~~comprising administering to the patient an effective amount of a compound as defined in claim 1.~~

5 (Canceled).

6 (Currently amended). ~~Use of a compound as defined in claim 1 in the manufacture of~~
A method of manufacturing a medicament for treating a patient as defined in claim 1 in need of
~~modulation of PPAR (for example PPAR α) activity comprising~~
using a compound as defined in claim 1.

7 (Currently amended). ~~The method of claim 4 or use of claim 6~~
wherein the patient is in need of an increase in PPAR activity and the compound is a PPAR agonist.

8 (Currently amended). ~~The method or use of claim 7~~

wherein the PPAR is PPAR α or PPAR γ .

9 (Currently amended). ~~The use of a compound as defined in claim 1 in the manufacture of a medicament for the treatment of a~~ The method of claim 6

wherein the medicament is for the treatment of a patient in need of modulation of body mass or modulation of increase in body mass, and/or in need of modulation of plasma insulin, plasma glucose, plasma triglycerides and/or plasma cholesterol.

10 (Currently amended). The method of claim 1 ~~or use of claim 9~~

wherein the patient is in need of reduction of body mass or prevention of increase in body mass, and/or in need of reduction of plasma insulin, plasma glucose, plasma triglycerides and/or plasma cholesterol.

11 (Currently amended). ~~The use of a compound as defined in claim 1 in the manufacture of~~ The method of claim 6 a

wherein the medicament is for the treatment of a patient who is overweight or obese and/or has diabetes, hyperlipidaemia, atherosclerosis, coronary heart disease, stroke, obstructive sleep apnoea, arthritis and/or reduced fertility, or is at risk of developing such a condition.

12 (Currently amended). ~~The use of a compound as defined in claim 1 in the manufacture of~~ The method of claim 6 a

wherein the medicament is for the treatment of a patient in need of an antitumour agent or an antiinflammatory agent or of modulation of lipid or eicosanoid status or function, or of modulation of a lipid metabolising or binding entity activity.

13 (Currently amended). The method of ~~treatment or use of any one of claims 1 to 12~~ wherein the compound is or comprises a perfluorooctanoic acid, or is more than 75% ~~(for example 80%, 90% or 100%)~~ linear perfluorooctanoic acid or a salt or ester thereof.

14 (Currently amended). The method of ~~treatment or use of any one of claims 1 to 12~~, wherein the compound is or comprises a perfluoroheptanoic acid or salt or ester thereof.

15 (Currently amended). ~~The compound, method or use of any one of claims 1 to 12~~ wherein the compound is a perfluoropentanoic acid or salt or ester thereof.

16 (Canceled).

17 (Currently amended). A screening method for identifying a drug-like compound or lead compound for the development of a drug-like compound comprising in which (1)

exposing a mammal ~~is exposed~~ to a compound as defined in claim 1 or derivative thereof,
and

~~(2) measuring at least one of the plasma insulin, glucose, cholesterol, and/or triglyceride level of the mammal is measured, and/or bodyweight of the mammal is measured, and/or lipid or eicosanoid status or function of the mammal is measured.~~

18 (Currently amended). The method of claim 17, further comprising
the step of selecting a compound on exposure to which the plasma insulin, glucose, cholesterol and/or triglyceride level of the mammal is changed or reduced, and/or bodyweight or bodyweight increase of the mammal is changed or reduced.

19 (Currently amended). A screening method for identifying a drug-like compound or lead compound for the development of a drug-like compound comprising in which (1)

exposing a compound as defined in claim 1 or derivative thereof ~~is exposed~~ to a PPAR polypeptide, and

~~(2) the measuring at least one of binding of the compound to the PPAR polypeptide is measured or the change in the activity of the PPAR polypeptide is measured.~~

20 (Currently amended). A screening method for identifying a drug-like compound or lead compound for the development of a drug-like compound comprising in which (1)

exposing a compound as defined in claim 1 or derivative thereof ~~is exposed~~ to a lipid metabolising or binding entity, ~~for example cyclooxygenase (for example cyclooxygenase I or cyclooxygenase II) or phospholipase A (for example phospholipase A2)~~ and

~~(2) measuring at least one of the binding of the compound to the lipid metabolising or binding entity is measured or the change in the activity of the lipid metabolising or binding entity is measured.~~

21 (Currently amended). A screening method for identifying a drug-like compound or lead compound for the development of a drug-like compound comprising in which (1)

exposing a cell ~~is exposed~~ to a compound as defined in claim 1, and

~~(2) measuring at least one of the phenotype (for example differentiation) and/or the eicosanoid biosynthesis of the cell is measured.~~

22 (Currently amended). The method of claim 21, further comprising

the step of selecting a compound on exposure to which at least one of the phenotype, ~~for~~

~~example differentiation, of the cell is changed, and/or the eicosanoid biosynthesis of the cell is changed, preferably reduced.~~

23 (Currently amended). The ~~use or~~ method of ~~any one of claims 1 to 12~~ wherein the compound is identified or identifiable by a the screening method of ~~any one of claims 17 to 22.~~

24 (Canceled).

25 (Currently amended). A food product comprising a foodstuff, and a compound as defined in claim 1 ~~or a compound identified or identifiable by a screening method of any one of claims 17 to 22, wherein the food is not laboratory rodent feed.~~

26 (Currently amended). A kit of parts of screening system comprising
(1) a library of compounds each as defined in claim 1, and
(2) a PPAR polypeptide or polynucleotide encoding a PPAR polypeptide, and/or a test mammal.

27 (Currently amended). A kit of parts of screening system comprising
(1) a library of compounds each as defined in claim 1, and
(2) at least one of a lipid metabolising or binding entity ~~(for example COXI or COXII or phospholipase A2 or lipoxygenase)~~ or a polynucleotide encoding a lipid metabolising or binding entity.

28 (Canceled).

29 (New). A method as in claim 4 wherein the PPAR activity is PPAR α activity.

30 (New). A method as in claim 6 wherein the medicament is for the treatment of a patient in need of modulation of PPAR activity.

31 (New). A method as in claim 30 wherein the PPAR activity is PPAR α activity.

32 (New). A method as in claim 30 wherein the medicament is for the treatment of a patient in need of an increase in PPAR activity and the compound is a PPAR agonist.

33 (New). The method of claim 6

wherein the medicament is for the treatment of a patient in need of reduction of body mass or prevention of increase in body mass, and/or in need of reduction of plasma insulin, plasma glucose, plasma triglycerides and/or plasma cholesterol.

34 (New). The method of claim 1

wherein the compound is identified or identifiable by the screening method of claim 19.

35 ((New). The method of claim 1

wherein the compound is identified or identifiable by the screening method of claim 20.

36 (New). The method of claim 1

wherein the compound is identified or identifiable by the screening method of claim 21.

37 (New). A food product as in claim 25

wherein the foodstuff is not laboratory rodent feed.